CALL 347-637-2631 TO JOIN BY PHONE AND ASK QUESTIONS
There are significant advances being made in multiple myeloma - more so than in any other cancer. Join us for this annual HealthTree Podcast for Multiple Myeloma with Robert Orlowski, MD, PhD of MD Anderson Cancer Center as we discuss the recent findings from the American Society of Hematology (ASH) meeting, key innovations being developed in myeloma and what patients can expect to see in 2023.
The show will review immunotherapy options, optimal combination therapies, targeted treatments and key learnings from top myeloma investigators.
Thanks to our episode sponsor, GSK
We appreciate your donations to support the HealthTree Foundation Podcast.
Welcome, Announcements & Introduction
A discussion with Robert Orlowski, MD, PhD including a review for 2023 of upcoming innovations for myeloma patients.
Audience is able to call in to the radio show. Call 347-637-2631 and press 1 on your keypad to ask Dr. Orlowski questions about what was discussed during our interview today.
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.
Robert Z. Orlowski, M.D., Ph.D., is Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics, where he is board-certified in medical oncology. Dr. Orlowski earned his doctoral degree in molecular biophysics and biochemistry from Yale University and his medical degree from the Yale University School of Medicine. He completed his internship and residency in Internal Medicine at Barnes Hospital at the Washington University in St. Louis School of Medicine. After his fellowships in Hematology and Medical Oncology at John Hopkins Sidney Kimmel Comprehensive Cancer Center, he joined the faculty at University of North Carolina in Chapel Hill. Following that, Dr. Orlowski accepted a position at The University of Texas MD Anderson Cancer Center in 2007 to lead the Myeloma Section in the Department of Lymphoma/Myeloma. His research interests include pathobiology of, novel therapeutic targets and mechanisms of drug resistance in myeloma which are documented in hundreds of scientific articles, book chapters, and presentations at conferences. Dr. Orlowski is an investigator on numerous clinical trials, and appointed Myeloma Committee Chair for SWOG.
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
+1 800 709 1113